Zepbound was approved on November 8, 2023, for long-term weight management in certain adults. People asking “when was Zepbound approved” sometimes see 2022 on its label. That earlier date belongs to tirzepatide’s first U.S. medicine, Mounjaro. Zepbound has its own decision letter.
When was Zepbound approved? The dated document
The FDA announcement carries the dateline “November 08, 2023.” The original approval letter identifies NDA 217806, the agency’s application file. Its signature page is dated November 8 too.
The letter specifies “as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management.” In everyday language, the medicine was reviewed alongside changes in food intake and activity, for losing weight and keeping it off.
The adult thresholds used body mass index, or BMI, a screening measure of weight relative to height. They were:
- BMI of 30 or higher, the obesity threshold.
- BMI of 27 or higher with at least one weight-related condition, such as high blood pressure or type 2 diabetes, a condition that causes high blood sugar.
That was a defined medical use, rather than an approval for anyone wanting to lose a few pounds.
What existed the day before
On November 7, 2023, tirzepatide was already a prescription medicine under another name. Mounjaro’s original decision, dated May 13, 2022, covered adults with type 2 diabetes.
The next day’s Zepbound decision gave the same active ingredient a separate weight-management brand and label. It did not rename Mounjaro or change every tirzepatide prescription into Zepbound. The Mounjaro versus Zepbound guide explains why the brand and the use written on a prescription still matter.
What the 2023 decision changed
Two trials supplied the weight-management evidence. SURMOUNT-1 studied 2,539 adults without diabetes over 72 weeks (Jastreboff and colleagues, New England Journal of Medicine, 2022). SURMOUNT-2 studied 938 adults with type 2 diabetes over the same period (Garvey and colleagues, The Lancet, 2023).
Both compared tirzepatide with placebo, an injection without the study medicine, alongside lifestyle support. Including people with and without diabetes mattered because the intended weight-management population included both. The separate guides explain SURMOUNT-1 results and SURMOUNT-2 results.
The original label, marked “Revised: 11/2023,” also carried a boxed warning, the label’s most prominent safety notice. It concerned tumors in thyroid C cells, one type of cell in the thyroid gland in the neck. Rats developed these tumors; whether that finding applies to humans is still unknown, and the current label carries the same boxed warning.
The label listed a personal or family history of medullary thyroid carcinoma, a rare thyroid cancer, and MEN 2, an inherited condition that raises the risk of certain tumors, as contraindications, meaning reasons the medicine must not be used. Approval came with those limits from the start.
2024: vials, a shortage decision, and sleep apnea
On August 27, 2024, Lilly announced single-dose Zepbound vials. FDA had approved the vial presentation in a March 2024 supplement, according to its December 19, 2024 shortage order. The vials changed how the branded medicine could reach patients; they did not add a new indication, meaning a use FDA reviewed.
Supply had its own timeline. Mounjaro joined the federal shortage list in December 2022; Zepbound pens joined in April 2024. FDA first declared the tirzepatide injection shortage resolved on October 2, 2024. After reconsideration, its December 19 order replaced that decision and again found the shortage resolved. National supply status did not guarantee every local pharmacy had every strength.
On December 20, 2024, Zepbound gained a second use: moderate-to-severe obstructive sleep apnea in adults with obesity. That condition involves repeated airway blockage during sleep. The decision again paired the medicine with a reduced-calorie diet and increased activity. It was not part of the November 2023 approval.
2025: the shortage transition wound down
The shortage decision changed the rules for compounded copies, preparations made by pharmacies rather than the brand’s manufacturer. FDA’s update dated March 10, 2025 recorded the end of the shortage-based grace period for state-licensed pharmacies after a March 5 court ruling. The corresponding period for registered outsourcing facilities, compounders subject to additional federal oversight, ended March 19.
Those dates concerned shortage-based exceptions. A compounded preparation remained a different product from Zepbound throughout.
2026: another device, Medicare access, and a revised label
The January 20, 2026 decision added Zepbound KwikPen, a branded pen containing four fixed doses for one patient. The current label also lists single-dose pens and vials, plus multi-dose vials. These are Zepbound presentations.
Medicare access changed separately, through a temporary program named for GLP-1, a gut-hormone signal involved in appetite and blood sugar. CMS’s provider page, last modified August 6, 2026, dates the GLP-1 Bridge’s start to July 1, 2026. This temporary program includes Zepbound KwikPen only among tirzepatide presentations, with specific eligibility requirements. Single-dose Zepbound pens and vials are excluded. The Medicare GLP-1 coverage guide explains that program.
As of November 5, 2026, the day this article was written, the current corrected label reads “Revised: 08/2026.” It revises an existing warning about diabetic retinopathy, damage to the light-sensitive tissue at the back of the eye. It retains monitoring for people with that history. This was a safety-language update, not another original weight-management approval. The same label records an earlier 2026 change: the suicidal-behavior warning carried since 2023 was removed in February 2026, after FDA's January 13, 2026 review found no increased risk with GLP-1 medicines.
On August 27, 2026, a federal appeals court upheld the judgment supporting FDA’s decision that the national shortage had ended. That supply decision remained separate from Zepbound’s original approval.
Why semaglutide is still a separate conversation
Semaglutide, the ingredient in Wegovy, acts on the GLP-1 signal. Tirzepatide also acts on GIP, a second gut-hormone signal involved in blood sugar and appetite. Different medicines need their own evidence and medical assessment.
As of November 5, 2026, the day this article was written, Lilly’s September 29, 2026 announcement discussed an indirect comparison with higher-dose Wegovy. “Indirect” means it compared results from separate trials, rather than assigning people between both medicines in one study. That analysis does not change Zepbound’s original approval date or predict which medicine suits one person.
What the anniversary means for a prescription now
Tirzepatide and semaglutide prescribed through Promise are dispensed by a licensed U.S. compounding pharmacy as compounded medications. They are different from an FDA-approved product: the formulations offered here are not FDA-approved. Zepbound’s authorization and its trial results do not establish matching results for a compounded preparation.
A licensed provider may still prescribe — that decision is between you and your doctor.
At Promise, a licensed U.S. provider reviews every request and may prescribe or decline on medical eligibility; not everyone qualifies. The anniversary marks the review of a specific branded product. An individual prescription still depends on the person’s history, the preparation being considered, and follow-up.
